Designs for phase I trials in ordered groups-Reference-Cited by-同舟云学术

Designs for phase I trials in ordered groups

Published:2016-09-14 Issue:2 Volume:36 Page:254-265
ISSN:0277-6715
Container-title:Statistics in Medicine
language:en
Short-container-title:Statist. Med.

Author:

Conaway Mark R.¹,Wages Nolan A.¹^ORCID

Affiliation:

1. Division of Translational Research and Applied Statistics, Department of Public Health Sciences; The University of Virginia; 22908 CharlottesvilleVA U.S.A.

Funder

National Cancer Institute of the National Institutes of Health National Institutes of Health

Publisher

Wiley

Subject

Statistics and Probability,Epidemiology

Reference30 articles.

1. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the national cancer institute organ dysfunction working group;Ramanathan;Journal of Clinical Oncology,2008

2. Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI organ dysfunction working group study NCI-6432;LoRusso;Clinical Cancer Research,2012

3. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer;Dasari;Investigational New Drugs,2013

4. Prados MD Lamborn KR Chang S Burton E Butowski N Malec M Kapadia A Rabbitt J Page MS Fedoroff A Xie D Kelley SK Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma Proceedings of the American Society of Clinical Oncology 22 Chicago, IL 2003 (abstract 394)

5. Phase I study of irinotecan with individualized dosing based on UGT1A1 polymorphism in Japanese patients with gastrointestinal cancer (UGT0601);Ura;Journal of Clinical Oncology,2008

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A model‐assisted design for partially or completely ordered groups;Pharmaceutical Statistics;2024-05-20

2. The quasi-CRM shift method for partially ordered groups;Contemporary Clinical Trials;2024-01

3. Isotonic Phase I Cancer Clinical Trial Design Utilizing Patient-Reported Outcomes;Statistics in Biopharmaceutical Research;2023-11-28

4. Isotonic design for phase I cancer clinical trials with late-onset toxicities;Journal of Biopharmaceutical Statistics;2023-01-06

5. Two‐stage subgroup‐specific time‐to‐event (2S‐Sub‐TITE): An adaptive two‐stage time‐to‐toxicity design for subgroup‐specific dose finding in phase I oncology trials;Pharmaceutical Statistics;2022-05-12